Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply

Aliment Pharmacol Ther. 2021 Mar;53(5):659. doi: 10.1111/apt.16251.

Authors

Stanislas Pol^{1

2

3}, Clovis Luzivika Nzinga⁴, Hélène Fontaine³, Fabrice Carrat^{4

5}; French ANRS CO22 Hepather cohort

Affiliations

¹ Université de Paris, Paris, France.
² INSERM U-1223, Institut Pasteur, Paris, France.
³ Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Unité d'Hépatologie, Paris, France.
⁴ Sorbonne Université, Institut National de la santé et de la Recherche Médicale, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
⁵ Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Antoine, Unité de Santé Publique, Paris, France.

PMID: 33566398
DOI: 10.1111/apt.16251

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antiviral Agents / adverse effects
Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / epidemiology
Europe / epidemiology
Guanine / analogs & derivatives
Hepatitis B virus
Hepatitis B, Chronic* / complications
Hepatitis B, Chronic* / drug therapy
Humans
Liver Neoplasms* / drug therapy
Liver Neoplasms* / epidemiology
Tenofovir / adverse effects

Substances

Antiviral Agents
entecavir
Guanine
Tenofovir